Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers

Surgery Clinical Trial

Official title:

Double-blinded, Placebo-controlled, Sequential Cohort, Multiple-Dose Escalation Study to Evaluate the Safety and Multiple Dose Pharmacokinetics of CT-044 HCl, a Reactive Species Decomposition Accelerant, in Healthy Human Volunteers

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04175743
• Other study ID #: CT044-002
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: December 4, 2019
• Est. completion date: September 2020

Study information

• Verified date: July 2020
• Source: Lotus Clinical Research, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted to assess safety, tolerability, and PK of CT-044 HCl in normal healthy volunteers, in a traditional sequential multiple ascending dose paradigm. The multiple-dose escalation is designed to mimic the manner in which the product (CT-044 HCl) would be used to manage ongoing pain in patients (i.e., multiple dosing).

Description:

Subjects meeting all inclusion and exclusion criteria will be randomized to receive CT-044 HCl or placebo in three successive dose escalating cohorts of 8 subjects each (2 placebo and 6 active drug per dose level). Subjects will receive multiple oral CT-044 HCl doses for 7 days. Subjects will be monitored in-house for vital signs, physical examination, electrocardiogram (ECG), safety laboratory testing and documentation of adverse signs and symptoms. Serial blood and urine samples will be collected to evaluate CT-044 HCl levels in plasma and urine.

Eligible subjects will be admitted to the Clinical Trial Unit on the day prior to dosing (Day -1) and remain in house until Day 9 (discharge day). Subjects will return to the Clinical Trial Unit on an outpatient basis for follow-up (Day 13, ± 1 day).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: September 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Body mass index within the range 18.5 to 32.0 kg/m2 (inclusive).

• Healthy subjects as determined by medical history, physical examination including neurological examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.

• Negative tests for hepatitis B surface antigen, hepatitis C virus antibodies and human immunodeficiency virus (HIV-1 or HIV-2) antibody, and syphilis.

• Nonsmokers (use of any nicotine containing product) or ex-smokers (have ceased smoking for at least 3 months and do not use any drug for smoking cessation.

• Negative screen for alcohol and drugs of abuse.

• Women must not be of childbearing potential by reason of surgery or at least 1 year post-menopausal (i.e., 12 months without menstrual period), or menopause.

• Men must be infertile (at least 3-months post-vasectomy), or truly abstinent of heterosexual intercourse, or heterosexual partner is not of childbearing potential or must agree to use an effective method of contraception. Men must agree to not provide sperm donation during that same period.

• Able and willing to be available for the duration of the study.

• Willing and able to give written informed consent to participate.

• Able to understand and comply with protocol instructions.

Related Conditions & MeSH terms

• Acute Pain
• Neuropathy
• Pain, Acute
• Surgery

Intervention

Drug:
• CT-044 HCl
CT-044 HCl is a reactive species decomposition accelerant

Locations

Country	Name	City	State
United States	Lotus Clinical Resarch,LLC	Pasadena	California

Sponsors (2)

Lead Sponsor	Collaborator
Lotus Clinical Research, LLC	CerSci Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum exposure level of CT-044	Occurrence of maximum exposure level of Cmax of 80 µg/mL and/or AUC0-24 of 450 hr.µg/mL (corresponding to average values obtained at the NOAEL doses in males rat and dog) has been reached in =2 subjects in a cohort or if it is expected to be reached in the planned next cohort.	49 days
Primary	Plasma Pharmacokinetic Concentration of CT-044	The PK data will be summarized by dose/cohort using appropriate statistics. Actual elapsed time from dosing will be used for the final plasma PK parameter calculations after database lock. Plasma PK samples collected every 8 hours for 32 hours.	32 Hours
Primary	Urine Pharmacokinetic Concentration of CT-044	The urine PK concentration of CT-044 will use individual data points to determine the concentration of CT-044 in subjects urine. Urine PK samples collected every 8 hours for 24 hours.	24 Hours